Lv35
350 积分 2025-07-27 加入
Nasopharyngeal carcinoma
2天前
已完结
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
10天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
14天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
15天前
已完结
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
16天前
已完结
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
16天前
已完结
Nasopharyngeal carcinoma
26天前
已完结
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
29天前
已完结
小细胞肺癌新辅助治疗疗效病理评估专家共识
1个月前
已完结
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study
1个月前
已完结
皖公网安备34019202002308
